The Novavax vaccine could become the fourth coronavine vaccine to be approved for emergency use by the US Food and Drug Administration. .
The pharmaceutical company is thus completing the last trials in the United States at record speed, after subjects have flocked in from the United States and Mexico. This is despite the fact that Novavax was lagging behind from the start, as the company had to start trials six to eight weeks later than expected.
The corona vaccines from BioNTech / Pfizer and Moderna have already been approved for emergency use in the United States, and Johnson & Johnson’s vaccine is also being approved.
The Phase Three trial of the Novavax vaccine, which took place in the UK, involved 15,000 people. The estimated efficacy of the vaccine is 89 percent, and analyzes also indicate that the vaccine is effective against the UK variant, B.1.1.7.
In a separate trial in South Africa, the effectiveness of the vaccine was reduced against the South African BB strain, which has also been found in Denmark. However, the vaccine reduced the risk of symptomatic disease by 60 percent, and this may indicate that the vaccine may also be relatively effective against this variant.
The director of the pharmaceutical company Novavax, Stanley Erck, expects that the UK will be the first country to approve the corona vaccine, and then the director reckons that many countries will follow suit “very, very quickly”, he tells the Financial Times.
And in the US, the FDA is also considering approving the vaccine on the already published British experimental data.
In the EU, the vaccines from BioNTech / Pfizer and Moderna are also approved for emergency use, as is the AstraZeneca vaccine, which has not yet been approved in the USA.
In December, the European Commission announced that it was in advanced negotiations with Novavax for the purchase of 100 million doses – with an option to purchase an additional 100 million doses.
On 3 February, the European Medicines Agency (EMA) launched an ongoing evaluation of the coravana vaccine from Novavax. The ongoing assessment was initiated to be at the forefront and save administrative time in the approval process without relaxing the requirements for documentation of the vaccine’s efficacy, safety and quality.
Source: www.berlingske.dk by www.berlingske.dk.
*The article has been translated based on the content of www.berlingske.dk by www.berlingske.dk. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!